Emergent BioSolutions, Inc., set to deliver anthrax vaccines early

Emergent BioSolutions, Inc., recently announced the largest single-week regulatory release of product for delivery to the U.S. government in the company’s history.

The company expects to complete shipments of 14.5 million doses of BioThrax to the Centers for Disease Control’s Strategic National Stockpile approximately three months ahead of the schedule agreed upon in its contract, according to 4-Traders.com.

Eight lots of BioThrax recently received regulatory release for delivery to the U.S. government, meaning they could be in the stockpile as early as June.

BioThrax is the only vaccine for protection from anthrax infection that has been licensed by the U.S. Food and Drug Administration.

"Emergent is pleased with its progress towards early completion of its original procurement contract to supply 14.5 million doses of BioThrax," Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions, Inc., said, according to 4-Traders.com.. "Upon completion of this delivery, anticipated to occur as early as June, the company will focus on delivering the additional 3.42 million doses under the modified procurement contract. With the recent request for proposal issued by the U.S. government, Emergent is also advancing discussions to supply 44.75 million doses of BioThrax over the next five years."

BioThrax is indicated for the immunization of adults with a high risk of exposure to anthrax. It is manufactured from a non-virulent strain of the bacteria Bacillus anthracis.

Emergent BioSolutions, Inc., has already delivered 42 million doses of the vaccine to the U.S. government and continues to do so under existing procurement contracts. Since 1998, 2.5 million military personnel have received 10 million doses of the vaccine.